EVANSTON, Ill., June 2, 2026
Researchers at Endeavor Health have developed a groundbreaking genetic screening tool designed to provide a more comprehensive assessment of an individual’s risk for coronary artery disease (CAD), the leading cause of death worldwide. The innovative test, known as GenProb-CAD, combines multiple genetic risk assessment strategies into a single integrated model, enabling clinicians to identify high-risk individuals with greater precision than traditional genetic testing methods. Findings from a large-scale study involving 450,000 individuals were recently published in Circulation: Genomic and Precision Medicine, highlighting the test’s potential to transform preventive cardiovascular care. By integrating both monogenic and polygenic genetic risk factors, including inherited risk associated with Lipoprotein(a), the test offers a broader and more accurate view of cardiovascular disease susceptibility. Researchers believe this next-generation approach could significantly improve early detection efforts and help healthcare providers intervene before life-threatening cardiac events occur.
Comprehensive Genetic Model Expands Cardiovascular Risk Detection
Traditional genetic screening for coronary artery disease typically relies on one of two approaches. Monogenic testing focuses on identifying rare but highly impactful genetic mutations linked to disease, while polygenic risk scoring evaluates the cumulative effect of numerous smaller genetic variations spread across the genome. While each approach provides valuable information independently, neither offers a complete picture of inherited cardiovascular risk.
Endeavor Health’s GenProb-CAD addresses this limitation by combining both methodologies into a unified screening platform. In addition to evaluating monogenic mutations, the test incorporates polygenic risk assessments for coronary artery disease and elevated Lipoprotein(a), a hereditary contributor to cardiovascular disease and high cholesterol. Researchers describe the approach as moving from a narrow diagnostic lens to a comprehensive genomic landscape capable of uncovering risk profiles that may otherwise remain undetected. Study results demonstrated that the integrated model identified significantly more high-risk individuals compared to traditional monogenic testing alone, expanding opportunities for earlier intervention and personalized disease prevention strategies.
Large-Scale Research Validates Clinical Utility
Advertisement
The development of GenProb-CAD was supported by one of the largest genomic analyses conducted in cardiovascular medicine, utilizing data from approximately 450,000 tested individuals. Researchers found that patients identified as high risk through the new genomic model exhibited cardiovascular disease risk levels comparable to those detected using conventional diagnostic tools such as blood lipid testing and electrocardiograms. Importantly, the predictive value of the test remained significant even after accounting for traditional cardiovascular risk factors, including cholesterol levels.
These findings suggest that genomic risk assessment can provide independent and clinically meaningful information capable of enhancing existing preventive care strategies. Investigators believe the ability to detect elevated risk years before symptoms emerge may allow physicians to implement lifestyle interventions, monitoring programs, and personalized treatment plans earlier in the disease process. Such proactive approaches could potentially reduce the incidence of heart attacks, strokes, and other cardiovascular complications among genetically predisposed individuals.
Precision Medicine Advances Preventive Cardiology
The introduction of GenProb-CAD represents a significant milestone in the evolution of precision medicine and genomic healthcare. Since 2014, Endeavor Health has been a national leader in integrating genomic testing into primary care through its Advanced Primary Care program, which has enrolled more than 80,000 patients to identify inherited risk factors associated with common diseases. The new cardiovascular screening tool further strengthens this commitment by translating advanced genomic science into routine clinical practice. Experts view the technology as an important step toward individualized healthcare, where prevention strategies are tailored to each patient’s unique genetic profile.
As healthcare systems increasingly embrace personalized medicine, integrated genomic screening tools such as GenProb-CAD may become valuable components of future cardiovascular prevention programs. By identifying at-risk individuals before symptoms develop, the technology has the potential to shift healthcare from reactive treatment to proactive disease prevention. The successful implementation of GenProb-CAD demonstrates how large-scale genomic research can directly impact patient care and improve outcomes in one of the world’s most prevalent and costly diseases.
Source: Endeavor Health press release
